Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration

Journal of Neuroinflammation

Volumn 5, Issue , 2008, Pages

  Tobinick, Edward L ^a,b   Gross, Hyman ^a,b  

^a Private Medical Group Inc   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; DONEPEZIL; ETANERCEPT; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CASE REPORT; COGNITION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILY HISTORY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; INTERVERTEBRAL DISKECTOMY; LABORATORY TEST; LOW BACK PAIN; LOW DRUG DOSE; MALE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; PATIENT POSITIONING; PHYSICAL EXAMINATION; PROSTATE CANCER; RECALL; SPINE FUSION; TASK PERFORMANCE; UNSPECIFIED SIDE EFFECT; VERTEBRAL CANAL STENOSIS; DRUG ANTAGONISM; DRUG EFFECT; INTRASPINAL DRUG ADMINISTRATION; PSYCHOLOGICAL ASPECT; TIME; TREATMENT OUTCOME;

AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SPINAL; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38549178015     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-5-2     Document Type: Article

References (72)

1. Griffin WS Stanley LC Ling C White L MacLeod V Perrot LJ White CL 3rd Araoz C: Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989, 86(19):7611-5. 298116 2529544 10.1073/pnas.86.19.7611
2. Mrak RE Griffin WS Interleukin-1, neuroinflammation, and Alzheimer's disease Neurobiol Aging 2001 22 6 903 8 10.1016/S0197-4580(01)00287-1 11754997
3. Akiyama H Barger S Barnum S Bradt B Bauer J Cole GM Cooper NR Eikelenboom P Emmerling M Fiebich BL Finch CE Frautschy S Griffin WS Hampel H Hull M Landreth G Lue L Mrak R Mackenzie IR McGeer PL O'Banion MK Pachter J Pasinetti G Plata-Salaman C Rogers J Rydel R Shen Y Streit W Strohmeyer R Tooyoma I Van Muiswinkel FL Veerhuis R Walker D Webster S Wegrzyniak B Wenk G Wyss-Coray T: Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21(3):383-421. 10.1016/S0197-4580(00)00124-X 10858586
4. Mrak RE Griffin WS: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26(3):349-54. 10.1016/ j.neurobiolaging.2004.05.010 15639313
5. Fillit H Ding WH Buee L Kalman J Altstiel L Lawlor B Wolf-Klein G: Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991, 129(2):318-20. 10.1016/0304-3940(91)90490-K 1745413
6. Perry RT Collins JS Wiener H Acton R Go RC: The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 2001, 22(6):873-83. 10.1016/S0197-4580(01)00291-3 11754994
7. Tarkowski E Blennow K Wallin A Tarkowski A: Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999, 19(4): 223-30. 10.1023/A:1020568013953 10471976
8. Tarkowski E Liljeroth AM Minthon L Tarkowski A Wallin A Blennow K: Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 2003, 61(3):255-60. 10.1016/S0361-9230(03)00088-1 12909295
9. Tarkowski E Andreasen N Tarkowski A Blennow K: Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003, 74(9):1200-5. 10.1136/jnnp.74.9.1200 12933918
10. Laws SM Perneczky R Wagenpfeil S Muller U Forstl H Martins RN Kurz A Riemenschneider M: TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat 2005, 26(1):29-35. 10.1002/humu.20180 15895461
11. Zou JY Crews FT: TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005, 1034(1-2):11-24. 10.1016/j.brainres.2004.11.014 15713255
12. Alvarez A Cacabelos R Sanpedro C Garcia-Fantini M Aleixandre M: Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 2007, 28(4):533-6. Epub 2006 Mar 29 10.1016/j.neurobiolaging.2006.02.012 16569464
13. Chiarini A Dal Pra I Whitfield JF Armato U: The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines. Ital J Anat Embryol 2006, 111(4):221-46. 17385278
14. Zuliani G Ranzini M Guerra G Rossi L Munari MR Zurlo A Volpato S Atti AR Ble A Fellin RF: Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 2007, 41(8):686-93. 10.1016/j.jpsychires.2006.02.008 16600299
15. Takeuchi H Jin S Wang J Zhang G Kawanokuchi J Kuno R Sonobe Y Mizuno T Suzumura A: Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 2006, 281(30):21362-8. 10.1074/ jbc.M600504200 16720574
16. Ramos EM Lin MT Larson EB Maezawa I Tseng LH Edwards KL Schellenberg GD Hansen JA Kukull WA Jin LW: Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol 2006, 63(8):1165-9. 10.1001/archneur.63.8.1165 16908746
17. Meme W Calvo CF Froger N Ezan P Amigou E Koulakoff A Giaume C: Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: Potentiation by beta-amyloid. Faseb J 2006, 20(3):494-6. 16423877
18. Lio D Annoni G Licastro F Crivello A Forte GI Scola L Colonna-Romano G Candore G Arosio B Galimberti L Vergani C Caruso C: Tumor necrosis factor-alpha -308A/G polymorphism is associated with age at onset of Alzheimer's disease. Mech Ageing Dev 2006, 127(6):567-71. 10.1016/ j.mad.2006.01.015 16516271
19. Csiszar A Labinskyy N Smith K Rivera A Orosz Z Ungvari Z: Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol 2007, 170(1):388-98. 1762698 17200210 10.2353/ ajpath.2007.060708
20. Tobinick E Gross H Weinberger A Cohen H: TNF-alpha modulation for treatment of Alzheimer's disease: A 6-month pilot study. MedGenMed 2006, 8(2):25. 1785182 16926764
21. Tobinick E: Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res 2007, 4(5):550-2. 10.2174/156720507783018217
22. Tweedie D Sambamurti K Greig NH: TNF-alpha Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. Curr Alzheimer Res 2007, 4(4):375-8. 10.2174/156720507781788873
23. Tan ZS Beiser AS Vasan RS Roubenoff R Dinarello CA Harris TB Benjamin EJ Au R Kiel DP Wolf PA Seshadri S: Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology 2007, 68(22):1902-8. 10.1212/01.wnl.0000263217.36439.da 17536046
24. Medeiros R Prediger RD Passos GF Pandolfo P Duarte FS Franco JL Dafre AL Di Giunta G Figueiredo CP Takahashi RN Campos MM Calixto JB: Connecting TNF-{alpha} Signaling Pathways to iNOS Expression in a Mouse Model of Alzheimer's Disease: Relevance for the Behavioral and Synaptic Deficits Induced by Amyloid {beta} Protein. J Neurosci 2007, 27(20):5394-5404. 10.1523/JNEUROSCI.5047-06.2007 17507561
25. Van Eldik LJ Thompson WL Ranaivo HR Behanna HA Watterson DM: Proinflammatory Cytokine Upregulation as a Therapeutic Target for Neurodegenerative Diseases: Function-Based and Target-Based Discovery Approaches. International Review of Neurobiology 2007, 82:278-297.
26. Amgen: Enbrel(R) package insert; and data on file. Thousand Oaks, CA 2007.
27. Tobinick E: The cerebrospinAl venous system: anatomy, physiology, and clinical implications. MedGenMed 2006, 8(1):53. 16915183
28. Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 2002, 298(5594):789-91. 10.1126/science.1074069 12399581
29. Yoshiyama Y Higuchi M Zhang B Huang SM Iwata N Saido TC Maeda J Suhara T Trojanowski JQ Lee VM: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53(3):337-51. 10.1016/j.neuron.2007.01.010 17270732
30. Small DH: Mechanisms of synaptic homeostasis in Alzheimer's disease. Curr Alzheimer Res 2004, 1(1):27-32. 10.2174/1567205043480573 15975082
31. LaFerla FM Oddo S Alzheimer's disease: Abeta, tau and synaptic dysfunction Trends Mol Med 2005 11 4 170 6 10.1016/j.molmed.2005.02.009 15823755
32. Bell KF Claudio Cuello A: Altered synaptic function in Alzheimer's disease. Eur J Pharmacol 2006, 545(1):11-21. 10.1016/ j.ejphar.2006.06.045 16887118
33. Beattie EC Stellwagen D Morishita W Bresnahan JC Ha BK Von Zastrow M Beattie MS Malenka RC: Control of synaptic strength by glial TNFalpha. Science 2002, 295(5563):2282-5. 10.1126/science.1067859 11910117
34. Stellwagen D Malenka RC: Synaptic scaling mediated by glial TNF-alpha. Nature 2006, 440(7087):1054-9. 10.1038/nature04671 16547515
35. Stellwagen D Beattie EC Seo JY Malenka RC: Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005, 25(12):3219-28. 10.1523/ JNEUROSCI.4486-04.2005 15788779
36. Wang Q Wu J Rowan MJ Anwy LR Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor Eur J Neurosci 2005 22 11 2827 32 10.1111/j.1460-9568.2005.04457.x 16324117
37. Rowan MJ Klyubin I Wang Q Hu NW Anwyl R: Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans 2007, 35(Pt 5):1219-23. 17956317
38. Zec RF Burkett NR Markwell SJ Larsen DL: A cross-sectional study of the effects of age, education, and gender on the Boston Naming Test. Clin Neuropsychol 2007, 21(4):587-616. 10.1080/13854040701220028 17613980
39. Smith T Gildeh N Holmes C: ThV Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry 2007, 52(5):329-32. 17542384
40. McKhann G Drachman D Folstein M Katzman R Price D Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-44. 6610841
41. American Psychiatric Association: Diagnostic and statistical manual of mental disorders
42. Tains JS Oliet SH: Glia: they make your memories stick! Trends Neurosci 2007, 30(8):417-24. Epub 2007 Jul 12 10.1016/j.tins.2007.06.007 17631972
43. Pickering M Cumiskey D O'Connor JJ: Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 2005, 90(5):663-70. 10.1113/expphysiol.2005.030734 15944202
44. Nasreddine ZS Phillips NA Bedirian V Charbonneau S Whitehead V Collin I Cummings JL Chertkow H: The MontreaA Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005, 53(4):695-9. 10.1111/j.1532-5415.2005.53221.x 15817019
45. Sjögren M Folkesson S Blennow K Tarkowski E: Increased intrathecal inflammatory activity in frontotemporal dementia: Pathophysiological implications. J Neurol Neurosurg Psychiatry 2004, 75(8):1107-11. 10.1136/ jnnp.2003.019422 15258209
46. Goodman JC Robertson CS Grossman RG Narayan RK: Elevation of tumor necrosis factor in head injury. J Neuroimmunol 1990, 30(2-3):213-7. 10.1016/0165-5728(90)90105-V 2229409
47. Shallice T Burgess PW: Deficits in strategy application following frontal lobe damage in man. Brain 1991, 114(Pt 2):727-41. 10.1093/brain/ 114.2.727 2043945
48. Eslinger PJ Damasio AR: Severe disturbance of higher cognition after bilateral frontal lobe ablation: Patient EVR. Neurology 1985, 35(12):1731-41. 4069365
49. Goddard CA Butts DA Shatz CJ: Regulation of CNS synapses by neuronal MHC class I. Proc Natl Acad Sci USA 2007, 104(16):6828-33. 1871870 17420446 10.1073/pnas.0702023104
50. Halassa MM Fellin R Haydon PG: The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 2007, 13(2):54-63. 10.1016/j.molmed.2006.12.005 17207662
51. Ralay Ranaivo H Craft JM Hu W Guo L Wing LK Van Eldik LJ Watterson DM: Glia as a therapeutic target: Selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 2006, 26(2):662-70. 10.1523/JNEUROSCI.4652-05.2006 16407564
52. Tancredi V D'Arcangelo G Grassi F Tarroni P Palmieri G Santoni A Eusebi F: Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett 146, 2:176-8. 1992 Nov 9 10.1016/ 0304-3940(92)90071-E 1337194
53. Abbott LF NelsoT SB: Synaptic plasticity: taming the beast. Nat Neurosci 2000 3(Suppl):1178-83. Review 10.1038/81453 11127835
54. Turrigiano GG Nelson SB: Homeostatic plasticity in the developing nervous system. Nat Rev Neurosci 2004, 5(2):97-107. Review 10.1038/ nrn1327 14735113
55. Chang EH Savage MJ Flood DG Thomas JM Levy RB Mahadomrongkul V Shirao T Aoki C Huerta PT: AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. Proc Natl Acad Sci USA 103(9):3410-5. 2006 Feb 28. Epub 2006 Feb 21 1413872 16492745 10.1073/ pnas.0507313103
56. Houweling AR Brecht M: Behavioural report of single neuron stimulation in somatosensory cortex. Nature 451, 7174:65-68. 10.1038/nature06447 18094684
57. Delbeuck X Van der Linden M Collette F: Alzheimer's disease as a disconnection syndrome? Neuropsychol Rev 2003, 13(2):79- 92. 10.1023/ A:1023832305702 12887040
58. Allen G Barnard H McColl R Hester AL Fields JA Weiner MF Ringe WK Lipton AM Brooker M McDonald E Rubin CD Cullum CM: Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol 2007, 64(10):1482-7. 10.1001/archneur.64.10.1482 17923631
59. Ross FM Allan SM Rothwell NJ Verkhratsky A: A dual role for interleukin-1 in LTP in mouse hippocampal slices. J Neuroimmunol 2003, 144(1-2):61-7. 10.1016/j.jneuroim.2003.08.030 14597099
60. Inglis TJ: PrinciTia aetiologica: taking causality beyond Koch's postulates. J Med Microbiol 2007, 56(Pt 11):1419-22. 10.1099/ jmm.0.47179-0 17965339
61. Zeng C Lee JT Chen H Chen S Hsu CY Xu J: Amyloid-beta peptide enhances tumor necrosis factor-alpha-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes. J Neurochem 2005, 94(3):703-12. 10.1111/j.1471-4159.2005.03217.x 16033420
62. Taylor DL Jones F Kubota ES Pocock JM: Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J Neurosci 2005, 25(11):2952-64. 10.1523/JNEUROSCI.4456-04.2005 15772355
63. McGeer PL McGeer EG: Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 2002, 8(6):529-38. 10.1080/ 13550280290100969 12476347
64. Klegeris A Walker DG McGeer PL: Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Res 1997, 747(1):114-21. 10.1016/S0006-8993(96)01229-2 9042534
65. Janelsins MC Mastrangelo MA Oddo S LaFerla FM Federoff HJ Bowers WJ: Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation 2005, 2:23. 1276812 16232318 10.1186/1742-2094-2-23
66. Hu W Ranaivo HR Roy SM Behanna HA Wing LK Munoz L Guo L Van Eldik LJ Watterson DM: Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett 2007, 17(2):414-8. 10.1016/j.bmcl.2006.10.028 17079143
67. Floden AM Li S Combs CK: Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 2005, 25(10):2566-75. 10.1523/ JNEUROSCI.4998-04.2005 15758166
68. Edwards MM Robinson SR: TNF alpha affects the expression of GFAP and S100B: Implications for Alzheimer's disease. J Neural Transm 2006, 113(11):1709-15. 10.1007/s00702-006-0479-5 16736247
69. De A Krueger JM Simasko SM: Glutamate induces the expression and release of tumor necrosis factor-alpha in cultured hypothalamic cells. Brain Res 2005, 1053(1-2):54-61. 10.1016/j.brainres.2005.06.044 16040010
70. Cacquevel M Lebeurrier N Cheenne S Vivien D: Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 2004, 5(6):529-34. 10.2174/1389450043345308 15270199
71. Blasko I Marx F Steiner E Hartmann T Grubeck-Loebenstein B: TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. Faseb J 1999, 13(1):63-8. 9872930
72. Yamamoto M Kiyota T Horiba M Buescher JL Walsh SM Gendelman HE Ikezu T: Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 2007, 170(2):680-92. 1851864 17255335 10.2353/ajpath.2007.060378